BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li(Dana-Farber Cancer Institute), Lauren Ambrogio(Broad Institute), Takeshi Shimamura(Brigham and Women's Hospital), Shigeto Kubo(Beth Israel Deaconess Medical Center), Masaya Takahashi(Beth Israel Deaconess Medical Center), Lucian R. Chirieac(Brigham and Women's Hospital), Robert F. Padera(Brigham and Women's Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Anke Baum(Boehringer Ingelheim (Austria)), Frank Himmelsbach(Boehringer Ingelheim (Germany)), Wolfgang J. Rettig(Boehringer Ingelheim (Austria)), Matthew Meyerson(Broad Institute), Flavio Solca(Boehringer Ingelheim (Austria)), Heidi Greulich(Broad Institute), Kah Keng Wong(Brigham and Women's Hospital)
Cited by 1,440Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis